Strong anti-viral responses in pediatric COVID-19 patients in South Brazil

Ethics Statement

This study was approved by the Institutional Review Board (IRB 30749720.4.1001.5330) at Hospital Moinhos de Vento and by the Ethics Committee at Universidade Federal de Ciências da Saúde (CAAE 30749720.4.3001.5345). Legal consent was obtained from all participants or their legal guardians. The study was conducted according to good laboratory practices and following the Declaration of Helsinki.

Patients

A prospective cohort study was carried out at Hospital Moinhos de Vento and at Hospital Restinga e Extremo Sul, both in Porto Alegre, southern Brazil. A convenience sample of adults and children older than 2 months were enrolled from June to December 2020 at either the outpatient clinics (OPC), emergency rooms (ER), or hospitalized. Subjects were screened if presenting cough and/or axillary temperature ≥37.8°C and/or sore throat. Both blood samples and respiratory samples collected through nasopharyngeal swabs were obtained at enrollment. Patients with the clinical diagnosis of COVID-19 and SARS-CoV-2 infection confirmed by RT-PCR were included in the study. Clinical and demographic data were collected at inclusion, following a standardized protocol. Disease severity was classified according to the World Health Organization classification after completing the follow-up questionnaire (15).

SARS-CoV-2 RT-q-PCR

A qualitative RT-PCR assay to SARS-CoV-2 was performed for all participants. Bilateral nasopharyngeal and oropharyngeal swabs were collected and placed in the same transport medium with saline solution and RNAlater®, RNA Stabilization Solution (Catalog number AM7021, Invitrogen™). MagMax™ Viral/Pathogenic Nucleic Acid Isolation Kit (Applied Biosystems) was used to extract viral RNA in the KingFisher Duo Prime System (ThermoFisher, USA) automated platform. The RT-PCR assay was performed in 10 µL total reaction, using Path™ 1-Step RT-qPCR Master Mix, CG (catalog number A15299, AppliedBiosystems) and TaqMan™ 2019-nCoV Assay Kit v1 (catalog number A47532, AppliedBiosystems) which comprises the SARS-CoV-2–specific targets (gene ORF1ab, gene S and gene N). As reaction control was used 5 µL (200 copies/µL) the TaqMan™ 2019-nCoV Control Kit v1 (catalog number A47533, AppliedBiosystems). QuantStudio 5 (ThermoFisher Scientific, USA) was used to perform the PCR.

PBMC isolation and cryopreservation

Blood was collected in EDTA tubes (Firstlab, PR, Brazil) and stored at room temperature before processing for PBMC isolation and plasma collection. Plasma was separated by centrifugation and cryopreserved. PBMCs were next isolated by density-gradient centrifugation using Ficoll–Paque™ PLUS (GE Healthcare®), and either studied directly or resuspended in FBS 5% DMSO and stored in liquid nitrogen until use.

Flow cytometry

Cells were thawed by diluting them in 5mL pre-warmed complete RPMI1640 medium (Sigma-Aldrich - R8758) containing 5% FBS and spun at 1500 rpm for 5 minutes. Supernatants were carefully removed, and cells were resuspended in PBS. After, were stained with the BD Horizon™ Fixable Viability Stain 510 together with antibodies for surface markers, as follows: anti-CD3-APC-H7 (clone SK7), anti-CD24-APC-H7 (clone ML5), anti-HLA-DR-APC-H7 (clone G46-6), anti-CD4-PerCP-Cy5.5 (clone RPA-T4), anti-CD27-PerCP-Cy5.5 (clone M-T271), anti-CD11c-PerCP-Cy5.5 (clone B-ly6), anti-CD14-PerCP-Cy5.5 (clone M5E2), anti-CD8-FITC (clone HIT8a), anti-IgG-FITC (clone G18-145), Lineage 2-FITC (cat. 643397), anti-CD16-FITC (clone 3G8), anti-CXCR5 (CD185)-BB515 (clone RF8B2), anti-CD19-APC (clone HIB19), anti-CD127-Alexa 647 (clone HIL-7R-M21), anti-CX3CR1-Alexa647 (clone 2A9-1), anti-CD69-APC (clone FN50), anti-CD38-PE (clone HIT2), anti-ICOS (CD278)-PE (clone DX29), anti-CD141-PE (clone 1A4), anti-CD66b-PE (clone G10F5), anti-CD137 (4-1BB)-PE (clone 4B4-1), anti-HLA-DR-PE-Cy7 (clone G46-6), anti-CD19-PE-Cy7 (clone SJ25C1), anti-CD25-PE-Cy7 (clone 2A3), anti-CD45RA-PE-Cy7 (clone L48), anti-IgM-BV421 (clone G20-127), anti-PD-1 (CD279)-BV421 (clone MIH4), anti-CD303-BV421 (clone V24-785), anti-CD56-BV421 (clone NCAM 16), anti-CCR7-BV421 (clone 2-L1-A) antibodies. For intracellular staining, cells were first stained for surface markers and subsequently fixed and permeabilized using the Transcription Factor Buffer Set (BD Biosciences-Pharmingen, USA), then stained with anti-Ki-67-BV421 (clone B56), anti-Perforin-Alexa 647 (clone δG9), and anti-Granzyme B-BV421 (clone GB11) antibodies. Following in vitro stimulation assays with specific peptides, cells were stained with the BD Horizon™ Fixable Viability Stain 510 and anti-CD3-PE-Cy7 (clone SK7), anti-CD4-PerCP-Cy5.5 (clone RPA-T4), anti-CD8-APC-H7 (clone SK1), anti-CCR7-BV421 (clone 2-L1-A), and subsequently fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences-Pharmingen, USA), then stained with anti-IFNγ-FITC (clone 4S.B3), anti-TNF (clone MAb11) and anti-IL-17-PE (clone SCPL1362) antibodies. All samples were analyzed using a BD Biosciences - FACSCanto II and FlowJo 10.7.1 software.

In vitro T cells stimulation assays

PBMC were thawed, assayed for viability, counted, and plated in 96-well plates at 3×10⁶ PBMCs/mL, 100 uL/well in RPMI1640 medium (Sigma-Aldrich - R8758) supplemented with 10% fetal bovine serum (100 IU of penicillin/mL, 100 μg of streptomycin/mL (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (R10H medium), and subsequently stimulated with peptide PepTivator SARS-CoV-2 Prot S (130-126-700 - Miltenyi Biotec, Germany), PepTivator SARS-CoV-2 Prot N (130-126-698 - Miltenyi Biotec, Germany) and PepTivator SARS-CoV-2 Prot M (130-126-702 - Miltenyi Biotec, Germany) at 1 μg/mL. PMA (50 ng/mL, Sigma, USA) plus ionomycin (1 μg/mL, Cayman chemical company, USA) and DMSO were used as positive and negative controls for stimulation, respectively. Stimulation with a CMV peptide pool at 2μg/mL (Mabtech, Sweden) was also performed, as a positive control for the assay. All treatments were submitted for 18h at 37°C and 5% CO₂. Three hours before harvesting, Golgi Plug (BD Biosciences, USA) 1μg/mL was added to each well. Cells were stained and analyzed for phenotype as described above.

ELISA

Plasma was tested for IgG and IgA antibodies to S-RBD protein (#RP-87678 - Invitrogen, USA) and N protein (kindly provided by Dr. Ricardo Gazinelli - Fiocruz Belo Horizonte, Brazil) using a protocol described in (16). Briefly, ELISA plates (Kasvi, Brazil) were coated overnight with 1μg/mL of SARS-CoV-2 Spike Protein (S-RBD). On the following day, plates were blocked for 1 h at room temperature with blocking buffer (3% Skim Milk Powder in Phosphate Buffered Saline (PBS) containing 0.05% Tween-20). Plasma samples were heat-inactivated at 56°C for 60 minutes and then serially diluted in 1% milk in 0.05% PBS-Tween 20 starting at a 1:25. Plasma was incubated for 2 h at 37°C. Secondary antibodies were diluted in 0.05% PBS-Tween and incubated for 1 h at room temperature. For both IgG, anti-human peroxidase produced in rabbit (#IC-1H01 - Rhea Biotec, Brazil), and IgA, anti-human peroxidase produced in goat (#A18781 - Invitrogen, USA), was used at a 1:10,000 dilution. The assay was developed with TMB Elisa Substrate - High Sensitivity (Abcam, United Kingdom) for 30 minutes, and the reaction stopped with 1M chloric acid. Readings were performed in an ELISA reader (Biochrom EZ 400), and O.D. at 450 nm was used to calculate the area under the curve (AUC), using a baseline of 0.07 for peak calculation (17).

Statistics

Percentages were used to describe categorical variables. Pearson’s Chi-square test was used to evaluate proportions among the children, severe and mild adults. Data normality assumptions were verified for continuous variables and summarized in terms of median and interquartile range (IQR). Two-tailed Kruskal-Wallis test followed by Benjamini-Hochberg correction for multiple comparisons was used to compare values among the groups. Principal Component Analysis (PCA) was employed to reduce the dimensions of 78 immunological variables generated by flow cytometry analysis, to explain the total variability with a smaller, new set of variables. Spearman correlations were performed between all variables (every set of two variables) and within sets of variables to identify clusters of correlated variables. In PCA of the variables grouped in clusters, variables containing redundant information were excluded. Comparison among groups regarding single variables or PC values was performed by non-parametric Kruskal-Wallis test, followed by 2 by 2 multiple comparisons with p-values adjusted accordingly. All analyses were performed either in GraphPad Prism v.9 or R and sometimes confirmed in Python. 3D analysis of PCA was plotted in Python. Scripts are detailed in supplemental materials.

Immune responses separate pediatric patients, adults with mild and severe disease from each other

Comprehensive immune profiling of PBMCs from pediatric and adult patients was performed using flow cytometry, generating 78 variables (frequencies of cell subpopulations and gMFI of activation markers). Gating strategies are detailed in Supplementary Figure 1 (A-H). To reduce the dimensionality of the numerous variables, a PCA analysis was carried out. This approach indicated that the three groups (pediatric patients; mild adult patients -AMD; and severe adult patients - ASD) separated from each other based on three of the new variables created, PC1, PC2, and PC3. PC1 separated the three groups, while PC2 separated mild patients from severe ones (Figure 1B). 3D plotting performed to include PC3 showed that children again separated from mild and severe adult patients (Figure 1C) and confirmed in 2D (Figure 1D). The PC scores from all three groups were plotted and the significance of these differences was analyzed by a Kruskal-Wallis (KW) test. Children had the highest mean score value for PC1 (2.765), followed by AMD (0.142) and ASD (−2.351), and these differences were highly significant (Figure 1E). For PC2, AMD had a mean score of 2.079, higher (p<0.0001) from children and ASD (mean scores of −1.585 and −1.180, respectively, p>0.999). PC3 scores were highest in children (mean=1.384) and significantly different from adults with mild (mean=−0.629; p<0.0047) and severe (mean=−0.247; p<0.0181) disease.

Principal components are calculated based on correlations among variables, and to interpret the meaning of each PC we analyzed the positive or negative contributions (loadings) of each variable in each PC. The variables with the main positive and negative contributions (loadings) are identified in Figures 1F, for PC1 and PC2; and 1G, for PC3. Respective loadings values are listed in Supplementary Table 1. PC1 had positive inputs mainly by IgM+ memory B cells, naïve B cells, and cDC1 DR expression; and main negative contributions by proliferating B cells; plasmablasts; and CX3CR1+ expression in dendritic cells (DC) (Figure 1F). That indicated that the group with the highest mean scores for PC1 (children) would be characterized by a profile of predominantly naive or low-affinity memory B cells, not activated/differentiated; and their dendritic cells would be high in DR, but low in CX3CR1. The opposite would be true for individuals with the lowest mean scores (ASD), while AMD would be characterized by an intermediate profile for these variables. The main positive influences for PC2 were T regs, mDCs, and TEMRA cells, indicating mild adult patients present significantly higher frequencies of these cell subpopulations. The main negative influences for PC2 were eosinophils, NK cells, and granulocytes (Figure 1F), and these should be the lowest in AMD. For PC3 (Figure 1G), the main positive contributions came from naive CD8+ T cells, naive CD4+ T cells, and pDCs; and main negative contributions were DCs; and expression of HLA-DR in mDC and cDC1. Because children had the highest scores for PC3, they should have significantly higher frequencies of such cells (and higher expression of HLA-DR in DCs) compared to both AMD and ASD. To verify these PCA interpretations, we compared them to the analysis of variance (Kruskal-Wallis) results performed among the three groups of patients regarding the three most relevant, positive (Figure 2A) and negative (Figure 2B) influencers, variables for PC1, PC2, and PC3. The comparison of the three groups for their variances regarding each variable agreed with the differences among them detected by PCA. A pattern that emerged from these two combined analyses was that children, AMD and ASD, separate from each other based mostly on differences in targeting innate inflammatory responses to inflamed tissues, and the state of activation of B and T lymphocytes.

• Download figure
• Open in new tab

Figure 2. Analysis of variance of the main variables contributing to principal components.

A-B, Kruskal-Wallis tests comparing values of each of the three immune variables that presented the highest influences – either positive (A) or negative (B) for PC1, PC2 and PC3. Each dot represents a patient, color coded: children – purple, adult with mild disease – green, and adult with severe disease – red. P values are indicated over brackets.

The percent of the total variability explained by these first principal components was low; the first three PCs together explained only 28.81% of the variance (Supplementary Table 1). This indicated that these 78 variables were not highly correlated as a whole. A correlation analysis using Spearman’ s coefficient confirmed this observation (Supplementary Figure 2), revealing a general pattern of moderate to weak correlations, but also identifying clusters of variables that were more correlated than others. These clusters represented six types of immune “signatures”: Proliferating/activated T cells; DCs; Granulocytes + Monocytes; NK cells; B cells; and memory T cells. Follicular helper T cells (Tfh) related variables were weakly correlated and were not considered as a cluster. We thus performed six separated PCAs for the identified clusters of variables, hypothesizing that they could bring more specific information to explain immunological differences among the three groups of patients. In this analysis, the first two PCs for each cluster were now explained a larger portion of the total variance (44.19, 63.17, 50.37, 67.35, 49.56, and 42.49%, respectively - Supplementary Table 1) among the three types of patients, and their distributions in children, AMD and ASD were analyzed. The results are shown in Figure 3 (A-D) and Supplementary Figure 3 (A-C), with the respective graphic representations for scores and loadings. We started by analyzing PCs formed by the innate cells’ signatures. Principal components for the clusters of Granulocytes+Monocytes (Figure 3A) and NK cells (Figure 3B), although derived from expressive correlations among their respective variables, did not separate the three groups of patients, indicating that the individuals were not significantly different for the variables that composed these PCs. That was intriguing because those variables had, as stated above, important contributions for the PC2 of all variables (Figure 1), but it also indicated that this contribution helped separate the groups mostly based on their correlations with other variables in the group of all variables, and not on the differences among groups for those variables alone. Although highly correlated among them (Supplementary Figure 2), variables composing the signatures for Granulocytes + Monocytes and NK cells did not separate the groups when used together in a PCA (not shown) and did not generate any new information.

• Download figure
• Open in new tab

Figure 3. Principal Component Analysis of innate cells immune signatures.

A-G, Principal component analysis of the clusters of patients (each dot representing a patient, color coded), according to the immune signatures (A, Granu⁺Mono, Granulocytes and Monocytes; B, NK cells; C, Dendritic Cells; D, Spearman correlation analysis of HLA-DR and CX3CR1 expression in DCS. For each signature, are displayed the PCA plot of PC1xPC2, the differences in scores of individuals for each PC; the loadings of the main variables contributing to each PC and Kruskal-Wallis tests comparisons of the major contributing variables values for each group of patients.

Findings in PCA for the DCs signature (Figure 3C) indicated that children were significantly separated from ASD, but not from AMD, with lower scores for PC1 (mostly CX3CR1 expression in DCs) and higher scores for frequencies of DCs (Figure 3C). HLA-DR expression in DCs subpopulations constituted negative contributions for PC1. This indicated that children, as well as AMD, would have more DCs than ASD, high in HLA-DR and low in CX3CR1. That was confirmed by the KW analysis of the three groups (Figure 3C). Spearman correlation analysis (Figure 3D) evidenced that CX3CR1 expression was negatively correlated with HLA-DR expression. These results suggested that high DCs frequencies in blood, with low CX3CR1, but high HLA-DR expression could be involved, or at least serve as markers, for mild disease. Inversely, low DCs frequencies, with high CX3CR1 expression, could be associated with more severe disease.

PCA for the clusters involving adaptive cells variables was performed next and are shown in Supplementary Figure 3. B cells (Supplementary Figure 3A, Supplementary Table 1) and T cell activation/proliferation (Supplementary Figure 3B, Supplementary Table 1) PCA corroborated a general pattern of response in children, either separating from the other groups (only sometimes grouping with AMD, apart from ASD). KW analysis of mean scores for each PC showed that in some cases children presented some significant differences from AMD. For example, PC1 of B cells recapitulated findings from the first analysis, mainly positively influenced for IgM+ B cells and naive cells, and showed children with significantly higher scores, compared to mild and ASD (p<0.01). Children were grouped with AMD (p=0.1599), and apart from ASD (p<0.0001), regarding PC1 of T cell activation/proliferation (Supplementary Figure 3B). The ASD had the highest scores for this PC, highly influenced by activated and proliferating CD4+ and CD8+ T cells, suggesting that adults with severe disease were characterized by higher frequencies of activated, Ki67+ T cells, and the opposite would be observed for children and AMD – though this was not always corroborated by the KW analysis. Finally, PCA for T cell memory clustered variables showed a trend to separate the three groups (Supplementary Figure 3C). PC1 scores, strongly positively influenced by naive T cells, but negatively influenced by effector memory T cells (TEM), significantly separated children from AMD (p=0.0005), and these somewhat separated from ASD (p=0.0410), indicating children and AMD would have lower frequencies of TEM and higher frequencies of naive T cells compared to ASD. Terminally differentiated memory CD4+ and CD8+ T cells (TEMRA) were strong positive influences for PC2, while expression of CD69 and CD137 in TEM cells negatively influenced PC2. Children and AMD, with high scores for PC2, did not differ from each other, suggesting they would both be characterized by higher frequencies of TEMRA cells than ASD, which in turn would have higher frequencies of activated, CD69+, CD137+, TEM cells. Confirmations of the interpretations of these PCs were again sought in the KW analysis for individual variables next to each PCA results (Supplementary Figure 3C), and also in Supplementary Figure 4 - which compiles all the remaining variables KW analyses results. This led us to note that for TEMRA, children differed from AMD and not from ASD. CD45RA, a marker upregulated both in naïve and TEMRA cells, has been shown to show different expression during the generation of memory pools of chronic infections (18) as well as in response to vaccination (19). Thus, the PCA could indicate possible differences for children in pathways for the generation of memory, although not confirmed in the KW comparisons. For TCM, there were no differences among groups (Supplementary Figure 4). Altogether, the patterns revealed by PCA indicated that children have higher frequencies of non-specific antigen inexperienced B and T cells and DCs, with high HLA-DR and low CX3CR1 expression. In some cases, children and AMD shared not only a mild presentation of the disease but also a similar immune profile. Finally, the immune profile of ASD was characterized by higher frequencies and markers of T and B cell activation and proliferation, TEM cells, and lower DCs with high expression of CX3CR1.

• Download figure
• Open in new tab

Figure 4. Antibody responses.

SARS-CoV-2 spike RBD IgA and IgG antibody titers determined by ELISA using serial dilutions of plasma. Individual titration curves for each individual (represented by a line, color coded) and analysis of variance (Kruskal-Wallis) of the values calculated as the area under the curve (AUC) for IgA (A) and IgG (B) are displayed. P values are displayed over brackets.

SARS-CoV-2 specific T cells and antibodies responses in children are comparable to the ones of adult patients

The characteristics of the non-specific immune profile of children led us to ask if they had effectively formed SARS-CoV-2 specific responses upon infection. Seroconversion after infection with SARS-CoV-2 patients with all forms of the disease has been described by several studies - reviewed in (20). Antibodies to the S protein, and more specifically to the RBD of this protein, are clinically considered a hallmark of infection, and frequently proposed as a correlate of protection. We thus compared children, AMD, and ASD for their RBD specific-IgA and IgG titers. On average, children presented levels of both IgG and IgA comparable to the adult patients (Figure 4). In our cohort, although some individuals from the ASD group presented higher levels of antibodies, differences among the groups were non-significant. Our results revealed that, even though children presented a generally naive, non-activated, immune profile, they had efficiently generated SARS-CoV-2 specific antibody responses, in levels that did not differ from the ones in AMD (p<0.103 for IgA; p>0.999 for IgG) or ASD (p<0.916 for IgA; p>0.999 for IgG) COVID-19 patients.

We next asked if children had generated specific effector T cell responses to SARS-CoV-2. There are four structural proteins in SARS-CoV-2: the spike glycoprotein (S), the envelope (E) protein, the membrane (M) protein, and the nucleocapsid (N) protein. Specific effector T cell responses have been described in adult COVID-19 patients, both with mild and severe disease (21,22), however fewer studies have focused on specific immune responses in pediatric patients infected with SARS-CoV-2. We measured the frequencies of CD4+T and CD8+T cells expressing TNFα, IFNγ, or IL-17 in response to stimulation by peptide pools of the S, N, and M proteins of the virus (Figure 5). Figure 5A shows representative flow cytometry plots of cytokine-producing CD4+ or CD8+ T cells upon stimulation with SARS-CoV-2 peptide pools. Negative (DMSO) and positive (PMA + ionomycin) control representative plots can be seen in Supplementary Figure 5. Children presented detectable CD4+ and CD8+ T cell responses upon stimulation with all three peptide pools (Figure 5B). When we compared types of responses in each group for the different peptide pools, children showed a significantly higher CD8+T TNFα+ response for the M (p<0.005) and for the N (p<0.0409) peptide pools than for the S pool (5B, upper right panel). This was not seen in adults, and although there was a trend for lower CD4+ TNFα+ responses in children, it was not significant. Supplementary Figure 6 shows the responses compared among the groups. About 30% of individuals – of all groups - did not show responding CD4+ T cells to the peptide pools; a higher frequency of individuals did not respond to the S pool compared to the M and N pools. In the ones that responded, CD4+ IL-17+ T cell responses were higher for all three peptide pools (about 1 log higher than INFγ and TNFα CD4+T cell responses). CD8+ T cell responses were, in general, more robust, although for S and M peptide pools there were still some individuals, though fewer, that did not respond to stimulation. The absence of response, in our sample, did not correlate with the early time of collection, as reported by (18). TNFα+ CD8+ T cell responses were about 1 log higher than what was detected for CD4+ T cells, for all peptide pools (Supplementary Figure 6). The IL-17+ CD4+T cells responses to stimulation by all three pools, were higher than the TNFα+CD4+ and INFγ+ CD4+ for all three groups. The differential TNFα+ cytotoxic response to M and N peptides seen in children led us to investigate levels of anti-N antibodies. Children made strong anti-N IgG levels, not different from AMD and ASD (Figure 6A). Anti-RBD IgA, but not IgG levels, correlated positively with CD4+ INFγ+ responses (Figure 6B). Interestingly, the TNFα+ cytotoxic responses to M and N peptide pools were inversely correlated with levels of anti-RBD and anti-N antibodies (Figure 6B). Anti-N antibody levels correlated positively with anti-N CD4+INFγ+ responses (Figure 6B). Taken together, these results indicate that children do generate specific humoral and effector cell responses upon infection with SARS-CoV-2, with a differential, higher cytotoxic response against proteins M and N, not associated with antibody responses to the spike protein.

• Download figure
• Open in new tab

Figure 5. Specific T cell responses.

A, gating strategies and typical plots of CD4+ and CD8+ T cells stimulated with peptide pools from structural proteins spike (S), membrane (M) and nucleocapsid (N), and analyzed by flow cytometry for cytokine production. B, Comparisons of effector T cells in each group - percentages of CD4+ or CD8+ cells, producing INFγ, TNFα or IL-17 in response to stimulation by each peptide pool. Each dot represents a patient, color coded: purple for children; green for adults with mild disease and red for adults with severe disease. All analyses are Kruskal-Wallis tests, and the p values are indicated over brackets. Significant differences are indicated by p values in a higher font.

• Download figure
• Open in new tab

Figure 6. Anti-N IgG response and correlation of specific responses.

A, SARS-CoV-2 anti-N IgG antibody titers determined by ELISA using serial dilutions of plasma. Individual titration curves for each individual (represented by a line, color coded) and analysis of variance (Kruskal-Wallis) of the values calculated as the area under the curve (AUC) for IgG (A) are displayed. P values are displayed over brackets. B, Matrix representing a Spearman correlation analysis of specific effector T cells responses (in percentages of positive CD4+ and CD8+ positive cytokine expressing cells in response to peptide pools) and the antibody response to the RBD of the spike protein and to the N protein (represented as values for the AUC). Correlations between the specific effector CD8+ T and CD4+ T cells frequencies, and the antibody (AUC – area under the curve) values for the RBD and N protein are highlighted.